ASTROCYTOMA, IDH-MUTANT, GRADE 2
Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 2 explained in plain language.
Never miss a new study
Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 2 trials appear
Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets genetic flaw in aggressive brain cancers
Disease control Recruiting nowThis study is testing an oral drug called safusidenib for adults with specific types of brain tumors that have a genetic change called an IDH1 mutation. The main goal is to see if the drug can safely control the tumor and delay its growth or return after standard treatments. The …
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE3 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New Drug-Radiation combo tested for aggressive brain cancers that return
Disease control Recruiting nowThis early-stage trial is testing whether combining an experimental drug called triapine with radiation therapy is safe for adults with glioblastoma or astrocytoma brain tumors that have returned after previous treatment. The study aims to find the highest dose of triapine that c…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 2
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC